The goal of this clinical trial is to determine whether telomere profiling and other biological aging hallmarks can help identify underlying mechanisms of persistent infertility in women with post-treatment unexplained infertility. The study also evaluates whether a personalized integrative treatment guided by these biomarkers can improve reproductive outcomes.
The study includes women aged 25 to 42 years who continue to experience infertility despite appropriate management of identifiable reproductive conditions and repeated attempts with assisted reproductive technologies (ART), such as intrauterine insemination (IUI) or in vitro fertilization (IVF).
The main questions this study aims to answer are:
* Can telomere and biological aging hallmarks profiling identify a biological aging phenotype associated with infertility? * Can an integrative treatment guided by these profiles improve clinical pregnancy outcomes?
Participants will:
* Undergo a baseline reproductive evaluation and blood-based assessment of telomeres and aging hallmarks. * Receive an integrative approach combining Traditional Chinese Medicine (TCM), targeted nutritional support, and standard fertility care. * Proceed with natural conception attempts or standard assisted reproductive technologies following the preconception phase. * Participants will be followed to assess pregnancy outcomes and changes in biological aging hallmarks.
Biological female participants aged 25 to 42 years.
Diagnosis of infertility defined as failure to conceive after at least 12 months of unprotected intercourse and/or repeated failure of assisted reproductive technologies (ART), including intrauterine insemination (IUI) and/or in vitro fertilization (IVF).
History of post-treatment unexplained or functionally idiopathic infertility, defined as persistent infertility despite adequate correction or management of identifiable reproductive conditions (e.g., endometriosis, polycystic ovary syndrome, hormonal imbalance, uterine factors).
Eligibility for natural conception attempts and/or assisted reproductive technologies according to routine clinical practice.
Current pregnancy or breastfeeding at the time of enrollment.
Known chromosomal abnormalities or genetic conditions directly impairing fertility (e.g., Turner syndrome).
Untreated severe male factor infertility precluding conception by natural or standard ART methods.
Active malignancy or history of cancer requiring systemic treatment within the past 5 years.
BEYOND GENOMiX SA, AG, Ltd
Lead sponsor
Praxis für Akupunktur und Chinesische Arzneimittel
Collaborator
Fertisuisse Ltd, SA, AG
Collaborator